Ruben Raychaudhuri

Assistant professor @fredhutch @uwmedicine former @pennIMresidents . interested in GU medical oncology, clinical trials

[Uromigos @Uromigos]

The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Omar Mian discusses: Metastasis-directed Therapy in Prostate Cancer.

[Ali Khaki @arkhaki]

Exciting to see the trial I wrote at @ASCO @AACR #VailWorkshop2019 published.

Thanks to mentor @PGrivasMDPhD and for the team @fredhutch carrying this through to completion!

#PDG6

[Ash Paul @pash22]

Prostate Cancer: A Review
https://t.co/RrW4RbFVCT via @RubenRaychaud et al

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#769 @ASCO #GU25  👉Congrats @RubenRaychaud @PGrivasMDPhD👉https://t.co/SCnL1Y04hU👉Ph2 trial of neoadj pembro + aMVAC in pts w/ non-urothelial MIBC #bladdercancer👉pCR 53%, median EFS 38 mos & median OS NR👉Promising data👇 @OncoAlert @urotoday @BladdercancerUS

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Please do read our letter to editor to @JCO_ASCO with regards to the recent publication of the ARANOTE trial. Until when shall we put up with inferior control arms?
Congratulations @abhenilmittal for raising awareness re this important issue.

https://t.co/UrHNIB20tF

[European Urology @EUplatinum]

Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial by @RubenRaychaud et al.

Full article: https://t.co/zxoOGnzpYh

[UroToday.com @urotoday]

#PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of pts with #mCRPC with homologous recombination DNA repair deficiency @RubenRaychaud @fredhutch. #ASCO24 written coverage by @rksayyid > https://t.co/FY7ssn7URE

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟#Genomic Correlates of Prostate-Specific Membrane Antigen #PSMA
Expression and Response to 177Lu-PSMA-617: A
Retrospective Multicenter Cohort Study🌟💫
@OncoAlert @PGrivasMDPhD @JessicaHawleyMD @RubenRaychaud @LauraGrahamMD @ColinCPritchard @PCFnews @PCF_Science
https://t.co/lobQhDcWxl
🔷️Purpose of the Study
🔹️ To evaluate the association between the mutational profile of metastatic castration-resistant prostate cancer (mCRPC) and the clinical efficacy of treatment with 177Lu-PSMA-617 (LuPSMA).

🔷️Methodology
🔹️ Retrospective multicenter analysis of 126 mCRPC patients who received LuPSMA and had next-generation sequencing (NGS) results.
🔹️ Comparison of treatment response, prostate-specific antigen progression-free survival (PSA PFS), and overall survival (OS) among genetically defined subgroups.

🚨Key Findings
🔹️ Presence of tumor suppressor gene (TSG) mutations was associated with shorter PSA PFS and OS.
🔹️Patients with DNA damage repair (DDR) gene mutations showed improved OS in multivariable analysis.
🔹️ PSMA expression did not show significant differences between DDR-deficient and DDR-proficient cohorts.
🔹️ Patients with ATM mutations demonstrated higher treatment response rates, longer PSA PFS, and better OS.
🔹️ #BRCA2 mutations were not associated with improved clinical outcomes.
🔹️ #CDK12 mutations were associated with poorer responses and shorter PSA PFS.

🔷️Conclusions
🔹️ Variability in clinical outcomes with #LuPSMA can be influenced by the tumor's mutational profile.
🔹️ Prospective studies are warranted to better define the clinical activity of LuPSMA in predetermined genomic subgroups.

🔷️ Limitations
🔹️ Retrospective nature of the study and small sample size of genomic subgroups.
🔹️ Limitations in measuring PSMA expression across multiple sites.

#GenomicMedicine #ProstateCancer #PrecisionOncology #LuPSMA #CancerResearch #mCRPC

[Avirup Guha, MBBS, MPH, FICOS, FACC, FAHA, FESC @avirupguha]

Our #prostatecancer group led by #MahaHussain @oreganruth #ShingLee #SanfordJeames at @AACR @ASCO methods in clinical cancer research conference #MCCR23 #VailWorkshop. Such excellent trials developed in this one of a kind workshop.